Dr. Lori Gore-Green | Women's Health Professional

Dr. Lori Gore-Green's Portfolio of Experience as a Women's Health Professional

  • Dr. Lori Gore-Green’s Biography
  • Texas Health Presbyterian Hospital
  • Dr. Lori Gore-Green Blog
  • Contact
  • Presentations by Dr. Lori Gore-Green
  • Multimedia

Debate Over Gynecology Tool Sheds Light On Regulation

September 27, 2014 by Dr. Lori Gore-Green

Dr. Lori Gore-GreenDoctors from all over the country are sticking by a gynecological tool even after a warning from the U.S. Food and Drug Administration about its ability to spread undetected cancer. As reported in a recent article from the Wall Street Journal, the face off between doctors and regulators is showcasing what some might call intransigence on the part of doctors, and others might call overreach on the part of the government. What is certainly clear is that quality gynecological care lies somewhere in the middle.

The device in question is called a laparoscopic power morcellator, and it is used by its proponents to remove benign uterine growths called fibroids. The tool is normally employed during routine hysterectomies to slice and remove the fibroids through small incisions. The issue with the morcellators is that they have the potential to leave tissue behind that can grow and then spread throughout the body, including tissue that has not been identified as malignant.

This potential threat prompted the warning from the FDA and caused many hospitals to stop using the tool, including Brigham and Women’s Hospital in Boston and Philadelphia’s Temple University Hospital. Many insurers across the country have stopped covering procedures involving morcellators.

However, there are gynecologists who believe that reports of the threat are unwarranted and continue to use the tool routinely. Doctors like Jeffrey Thurston of Dallas say that the treatments he performs with his patients are between he and his patient, and that regulators are simply interfering. In his practice, he has patients sign a release that states that the risk of spreading undetected sarcoma is somewhere between 1 in 300 and 1 and 1000. He also tells his patients verbally that he does not believe those numbers.

In the tug of war between the FDA and doctors, it can be difficult for patients to know whom to trust. Where one stands on the use of morcellators may have more to do with politics than any insights on patient welfare.

Read the whole story at Wall Street Journal.

Filed Under: Dr. Lori Gore-Green Tagged With: doctors, Dr. Lori Gore-Green, FDA, Food and Drug Administration, laparoscopic power morcellator, LPM, medical, OB/GYN, physician, tools

Ovulation Causes New Attractions

February 26, 2014 by Dr. Lori Gore-Green

 

Dr. Lori Gore-GreenIn an interesting analysis done by UCLA researchers on studies about how a woman’s mate preference may change throughout the month due to her menstrual cycle. As any living being has a preference or a “type” of individual they find themselves most attracted to, it is always subject to change, but especially during ovulation.

In an article on medicalnewstoday.com, professionals in the medical industry explain that when a woman is ovulating, she tends to be more attracted to the masculine body types and features, dominance, and a particular scent. These sexy men remain attractive; however, they are not necessarily that same woman’s first choice for a lifetime partner. This debate about preference changes has been ongoing since the late 90’s.

One particular study showed that a woman who considers her current male partner as extremely attractive and a sexy man, she is less likely to have a change in preference during ovulation than a woman whose male partner is considered less attractive (even if they have all the best characteristics a man could have). The study seems to make sense, keeping the topic consistent. If a woman’s existing partner is already the masculine, charming man, chances are she just has a stronger sense of attraction during ovulation but to that same man.Symmetrical, masculine facial structure reads more attractive in many cases.

Body scents seem to be one of the strongest preference factors during ovulation. In several studies, women were asked to smell shirts worn by men of all shapes and sizes. The shirts that smelled the best to these women were of symmetrical men. Symmetrical men (and animals) are men with a larger physique, better health, and more distinct sexual body parts. The root of preference change within studies is said to be from women’s ancestry. Symmetrical bodies and faces of these men may be a sign of genetic quality. As a result, the women who preferred these particular, masculine, sexy men are more likely to have children with strong, quality genes that will benefit them in terms of reproduction and survival.

Humans are not the only beings that have a change in preference while going through different phases of fertilization. Just one example is chimpanzees. Female chimps have sex with multiple male chimps during their ovulation period – and they are chimps that they would not have sex with when they’re not ovulating.

This is natural. If a woman is aware that this may happen, it is going to be easier for her to ignore these feelings and thoughts by telling herself that it is because she is ovulating. As living beings should always do, we must let nature take its course and be disciplined and educated enough to know what is happening.

Filed Under: Dr. Lori Gore-Green Tagged With: attraction, Dr. Lori Gore-Green, Gynecology, menstrual cycle, menstruation, OB/GYN, Obstetrics, ovulation, physician, preference changes, scents drive attraction, women's changes

« Previous Page

RSS Medical News

  • Telehealth Geriatric Cancer Assessment Passes Phase III Test in Low-Resource Setting
  • Removed ACIP Members Say 'U.S. Vaccine Program Critically Weakened'
  • Fecal Transplant Noninferior to Vancomycin for Initial C. Diff Therapy
  • Second Patient Dies After Gene Therapy for Duchenne Muscular Dystrophy
  • VA Disputes Story Asserting That New Rules Allow Docs to Discriminate
  • Adding Polivy to Standard of Care Boosts Survival in Relapsed/Refractory DLBCL
  • Steatotic Liver Disease: Clear-Cut Liver, Mortality Risks Tied to Subclasses
  • BTK Inhibitors for Multiple Sclerosis

Dr. Lori Gore-Green: Links

  • Dr. Lori Gore-Green | Gynecology and Obstetrics
  • Dr. Lori Gore-Green |Community Service
  • Dr. Lori Gore-Green Community Service
  • Info

Return to top of page

Copyright © About Dr. Lori Gore-Green ·